93. Primary biliary cholangitis
230 clinical trials,   215 drugs   (DrugBank: 51 drugs),   34 drug target genes,   107 drug target pathways

Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03082937
(ClinicalTrials.gov)
January 31, 201727/2/2017An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy SubjectsAn Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male SubjectsOrphan Cholestatic Liver Diseases;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome;Primary Biliary CirrhosisDrug: 3 mg [14C]-A4250 capsuleAlbireoNULLCompleted30 Years65 YearsMale6Phase 1United Kingdom
2NCT02360852
(ClinicalTrials.gov)
January 201514/1/2015IBAT Inhibitor A4250 for Cholestatic PruritusAn Exploratory, Phase IIa Study to Demonstrate the Safety and Efficacy of A4250 in Patients With Primary Biliary Cirrhosis and Cholestatic PruritusBiliary Cirrhosis, PrimaryDrug: A4250Sahlgrenska University Hospital, SwedenAlbireoTerminated18 Years80 YearsAll9Phase 2Sweden
3EUCTR2014-004070-42-SE
(EUCTR)
09/12/201415/10/2014Study to Demonstrate the Efficacy and Safety of A4250 in Patients withPrimary Biliary Cirrhosis and Cholestatic PruritusAn Exploratory, Phase IIa Cross-Over Study to Demonstrate the Efficacyand Safety of A4250 in Patients with Primary Biliary Cirrhosis andCholestatic Pruritus Primary biliary cirrhosis complicated by cholestatic pruritus.;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Code: A4250Sahlgrenska AcademyNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2aSweden
4NCT02963077
(ClinicalTrials.gov)
July 20131/11/2016A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy SubjectsOrphan Cholestatic Liver Diseases;Primary Biliary Cirrhosis;Progressive Familial Intrahepatic Cholestasis;Alagille SyndromeDrug: A4250;Drug: CRC (A3384);Drug: Questran;Drug: PlaceboAlbireoNULLCompleted18 Years60 YearsBoth94Phase 1NULL